SubHero Banner
Text

Hemlibra® (emicizumab-kxwh) – New orphan drug approval

November 16, 2017 – The FDA announced the approval of Genentech’s Hemlibra (emicizumab-kxwh), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII [FVIII] deficiency) with FVIII inhibitors.

Download PDF